Acceptability of an organ inventory for cancer screening across gender identity and intersex status
Menée aux Etats-Unis à partir d'une enquête auprès de 333 personnes, cette étude évalue, dans le cadre du dépistage des cancers, l'acceptabilité et l'efficacité d'un inventaire d'organes comme alternative aux questions sur le genre et/ou le sexe assigné à la naissance
Objectives : To evaluate the acceptability and performance of an organ inventory as an alternative to asking about gender and/or sex assigned at birth in cancer screening.
Methods : We fielded an online, self-administered survey to a convenience sample of English- or Spanish-speaking transgender and gender-diverse (TGD), intersex, and cisgender people (>/=15 years) in the US. The survey contained an organ inventory developed with community input and questions regarding acceptability. The primary outcome was organ inventory acceptability by the four-item Acceptability of Intervention Measure (AIM). Additional outcomes included inter-method screening agreement between the organ inventory, gender, and sex assigned at birth.
Results : In 2022, 333 eligible individuals completed the survey; 44.4% cisgender, 34.2% TGD, and 14.1% intersex. Overall, participants rated the organ inventory as acceptable (median AIM score = 18/20, IQR: 16-20). Most (73%) found it easy to understand, and comfortable to complete (65%). Cancer screening eligibility varied based on the method used; relying solely on gender or sex data would have missed some eligible participants that the organ inventory identified.
Conclusions : Using an organ inventory as an alternative to gender or sex-based screening questions was acceptable, and has implications for addressing cancer screening disparities.
Journal of the National Cancer Institute , article en libre accès, 2023